Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ)

• Company Description    Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 101

• Price / Volume Information    Yesterday's Closing Price: $6.36 Daily Weekly Monthly 20 Day Moving Average: 453,830 shares Shares Outstanding: 38.46 (millions) Market Capitalization: $244.58 (millions) Beta: 1.08 52 Week High: $10.60 52 Week Low: $2.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.97% -6.90% 12 Week 67.37% 88.10% Year To Date 134.69% 186.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 64 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 857-259-5340 fax: - investors@voyagertherapeutics.com http://www.voyagertherapeutics.com

• General Corporate Information    Officers Michael Higgins - Chief Executive Officer and President Julie Burek - Vice President of Finance Mark Levin - Director Jim Geraghty - Director Steven Hyman - Director Peer Information Voyager Therapeutics, Inc. (CORR.) Voyager Therapeutics, Inc. (RSPI) Voyager Therapeutics, Inc. (CGXP) Voyager Therapeutics, Inc. (BGEN) Voyager Therapeutics, Inc. (GTBP) Voyager Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92915B106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 38.46 Most Recent Split Date: (:1) Beta: 1.08 Market Capitalization: $244.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.22 Price/Cash Flow: - Price / Sales: 7.75 EPS Growth vs. Year Ago Period: 3.45% vs. Previous Quarter: -473.33% Sales Growth vs. Year Ago Period: -89.88% vs. Previous Quarter: -97.66% ROE 03/31/22 - -76.83 12/31/21 - -66.35 09/30/21 - -76.02 ROA 03/31/22 - -34.93 12/31/21 - -34.52 09/30/21 - -41.59 Current Ratio 03/31/22 - 1.68 12/31/21 - 2.68 09/30/21 - 4.73 Quick Ratio 03/31/22 - 1.68 12/31/21 - 2.68 09/30/21 - 4.73 Operating Margin 03/31/22 - -224.48 12/31/21 - -190.30 09/30/21 - -584.71 Net Margin 03/31/22 - -224.48 12/31/21 - -190.30 09/30/21 - -584.71 Pre-Tax Margin 03/31/22 - -224.48 12/31/21 - -190.29 09/30/21 - -584.70 Book Value 03/31/22 - 1.97 12/31/21 - 2.50 09/30/21 - 2.30 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©